• Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environment
  
  
  
   
• The FDA requires that biomarker testing to select patients for registration trials must be performed in a CLIA-certified laboratory environment
  
  
  
   
• CLIA certification for the Allarity Therapeutics Medical Laboratory is a critical strategic initiative to streamline the development of Allarity’s lead agent, stenoparib
  
  
  
  
  • Positions Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified partner for European companies pursuing U.S. clinical trials or commercialization
     

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.